Ultra-small implanted neurostimulation device for the treatment of Obstructive Sleep Apnea

Informazioni relative al progetto

Nyxoah

ID dell’accordo di sovvenzione: 729044

DOI

10.3030/729044

Progetto chiuso

Data della firma CE 21 Maggio 2016

Data di avvio 1 Giugno 2016

Data di completamento 30 Settembre 2016

Finanziato da

• SOCIETAL CHALLENGES - Health, demographic change and well-being

Costo totale

€ 71 429,00

Contributo UE

€ 50 000,00

Coordinato da

NYXOAH SA
Belgium

Periodic Reporting for period 1 - Nyxoah (Ultra-small implanted neurostimulation device for the treatment of Obstructive Sleep Apnea)

Periodo di rendicontazione: 2016-06-01 al 2016-09-30

Sintesi del contesto e degli obiettivi generali del progetto

Nyxoah project aims to introduce to the market a tiny HypoGlossal Nerve Stimulation (HGNS) system for the treatment of moderate to severe OSA patients who are not compliant with CPAP therapy. The key objectives of the project are to gather sufficient clinical evidence to commercialise the system as a CE certified medical device in Europe.

Lavoro eseguito dall’inizio del progetto fino alla fine del periodo coperto dalla relazione e principali risultati finora ottenuti

During the Phase 1 Feasibility Assessment, Nyxoah accomplished a full analysis of the business potential of the Nyxoah’s GenioTM. Throughout the duration of the project, Nyxoah increased its knowledge of the medical device market, including regulations, medical device reimbursement standards, market size and competitors.
In the feasibility study, Nyxoah estimated that there are around 4.6 million OSA sufferers in Europe who need an alternative solution to treat this sleep disorder breathing. Nyxoah decided to primarily target already diagnosed patients who are non-compliant with CPAP (700K) or refuse CPAP (100K), sizing the potential market at 800K patients.

Progressi oltre lo stato dell’arte e potenziale impatto previsto (incluso l’impatto socioeconomico e le implicazioni sociali più ampie del progetto fino ad ora)

Nyxoah’s disruptive technology will promote health and wellbeing, and improve patient quality of life. Nyxoah proposes an innovative OSA treatment for patients and sleep specialists. Nyxoah’s GenioTM will offer a minimally invasive, effective and easy-to-use OSA alternative therapy to millions of OSA sufferers and thousands of sleep specialists.

Nyxoah’s GenioTM implant

Nyxoah’s GenioTM patch

Nyxoah’s GenioTM